Western Michigan University

ScholarWorks at WMU
Master's Theses

Graduate College

8-2004

Mechanism of Chromium Reduction of Benzo[A]Pyrene
Diolepoxide Mutagenesis in Human Fibroblasts
Cara Suzanne Kriss

Follow this and additional works at: https://scholarworks.wmich.edu/masters_theses
Part of the Biology Commons

Recommended Citation
Kriss, Cara Suzanne, "Mechanism of Chromium Reduction of Benzo[A]Pyrene Diolepoxide Mutagenesis in
Human Fibroblasts" (2004). Master's Theses. 4331.
https://scholarworks.wmich.edu/masters_theses/4331

This Masters Thesis-Open Access is brought to you for
free and open access by the Graduate College at
ScholarWorks at WMU. It has been accepted for inclusion
in Master's Theses by an authorized administrator of
ScholarWorks at WMU. For more information, please
contact wmu-scholarworks@wmich.edu.

MECHANISM OF CHROMIUM REDUCTION OF BENZO[A]PYRENE
DIOLEPOXIDE MUTAGENESIS IN HUMAN FIBROBLASTS

by
Cara Suzanne Kriss

A Thesis
Submitted to the
Faculty of The Graduate College
in partial fulfillment of the
requirements for the
Degree of Master of Science
Department of Biological Sciences

Western Michigan University
Kalamazoo, Michigan
August2004

Copyright by
Cara Suzanne Kriss
2004

ACKNOWLEDGEMENTS
I would like to thank Dr. David Reinhold for being patient with me in all
of my mistakes and uncertainty. You have showed me what it means to be a good
student and researcher. I would also like to thank Dr. Bruce Bejcek and Dr. Bryan
Tripp for reading this manuscript and giving unhindered advice. Finally, I want to
acknowledge my family and friends who gave me the strength and purpose to
fulfill this chapter in my life.
Cata Suzanne Kriss

11

MECHANISM OF CHROMITJM REDUCTION OF BENZO[A]PYRENE
DIOLEPOXIDE MUTAGENESIS IN HUMAN FIBROBLASTS
Cara Suzanne Kriss, M.S.
Western Michigan University, 2004
Environmental agents can cause an increase in cellular stress and damage
DNA which can lead to diseases such as cancer. Chromium produces cellular
stress by increasing the reactive oxygen species through a Fenton-like reaction,
where chromium reacts with hydrogen peroxide to form hydroxyl radicals.
Benzo[a]pyrene is an environmental carcinogen that is metabolized by
cytochrome p450 enzymes into benzo[a]pyrene diolepoxide (BPDE). BPDE is
highly reactive with DNA producing large DNA-adducts primarily on guanine
nucleotides. The primary intracellular pathway by which mammalian cells remove
damaged DNA caused by bulky mutagens is nucleotide excision repair. We have
found that, in BPDE treated cells the addition of chromium significantly decreases
the frequency of mutations in the hypoxanthine phosphoribosyltransferase
(HPRT) gene. Using a 32P-postlabeling system it was found that the antagonistic
decrease in mutant frequency was due to a significant decrease in the number of
adducts produced by BPDE. Using cell lines deficient in various DNA repair
mechanisms, it was discovered that this reduction may involve an increase in
global genomic repair, which is a sub-pathway of nucleotide excision repair. The
way in which chromium elicits this increase of repair is not yet characterized, but
it appears to be independent of the p53 protein.
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CHAPTER!
INTRODUCTION
Cancer
Cancer is a disease state characterized by chromosomal abnormalities, cellular
transformation and uncontrolled cell growth. The uncontrolled growth of cells is
triggered by the abnormal expression of genes that are normally regulated through
intracellular processes. It has been discovered that cancerous cells form through a
long-term process of initiation, promotion and progression. Initiation is caused by a
permanent transformation within a normal cell that gives rise to an inheritable change
in gene expression or function. Promotion is the continued growth and expansion of
the initiated cells. These transformed cells then progress in a step-wise manner into
genotypically and phenotypically altered cells. Occasionally, cancerous cells will
also metastasize by spreading to other sites not directly affected by the original
initiation (Cooper, 1992; Mishra, et al., 1981).
One of the most·common mechanisms for abnormal gene activity is DNA
modification. There are several known compounds that modify cellular DNA; some
of these have little affect on the translated protein, yet some drastically change the
protein by either causing it to be overly active, causing it not to be present, or by
producing a non-functional protein. These possibilities may therefore lead to changes
in the normal functioning of intracellular systems. Yet, cancer is a multi-step process
and one modification of the DNA doesn't give rise to cancer.
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Cancers can be produced from environmental agents such as sunlight, car
exhaust and metals'. While ultraviolet light can directly damage DNA, other mutagens
like xenobiotics, and polycyclic aromatic hydrocarbgons require activation before
they become mutagenic (Fang, 2001; Huberman and Sachs, 1973). Mutagens that
cause the cells to undergo transformation so that they aquire cancer-like
characteristics are called carcinogens. Over the years many studies have been done on
the effects of individual carcinogens on both cultured cells and whole animals;
however, the simultaneous treatment of two or more carcinogens provides a more
comprehensive view of the interactions between various carcinogens and between the
carcinogens and the cells.

Metal Carcinogenesis

Metals are found ubiquitously at low concentration levels and humans are
exposed to metals from both environmental and industrial sources. Metals that are
known as potential carcinogens include arsenic, beryllium, cobalt, cadmium,
chromium, nickel, manganese, platintim, and selenium (IARC, 1987). Recent
evidence shows that there are several different mechanisms by which metals exert this
carcinogenic effect; and the overall carcinogenic potential depends on the
bioavailability of the metal, the affinity each metal has for intracellular components
and its rate of uptake into the cell (De Flora, 2000). Although there isn't a common
mechanism by which metals induce cytotoxicity- and carcinogenicity, the most
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. common methods include: DNA strand breaks, which only occur at doses that reduce
cloning efficiency by greater than 50%, (Snyder, 1988), DNA-DNA crosslinking,
DNA-protein crosslinking, and oxidative DNA damage (Singh, 1998; De Flora,
2000). Of these methods, oxidative DNA damage caused by oxidative stress is the
most discussed mechanism (Leonard et al., 2004; Dally & Hartwig, 1997). Oxidative
stress occurs from the generation of free radicals and reactive oxygen species (ROS).
Transition metals form reactive oxygen species by using Fenton/Haber Weirs
chemistry and autoxidation. During this process, increasing levels of H2O2, hydrogen
peroxide, are produced by the reaction between molecular oxygen and metals
(equations 1 and 2), via a damaging intermediate, superoxide (02) ion. Additionally,
metals can reduce hydrogen peroxide, a common by-product of metabolism, to
produce damaging hydroxyl radicals (equation 3) (Ding et al., 2002; Liu et al., 2001).

(1) Cr (V)+ 02 ➔ Cr (VI)+ 02(2) Cr (V) + 02- + 2H+ � H2O2 + Cr (VI)
(3) Cr (V)+ H2O2 ➔ Cr (VI)+ ·OH+ Ol

f

ROS have been shown to increase the oxidative potential within cells thereby
facilitating point mutations in the DNA, and causing strand breaks and/or
transformations within the cell (Ye et al., 1999). They are also thought to be involved
in the activation of p53 protein by chromium (VI) (Wang et al, 2000). Changes in the
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DNA at critical sites like ·oncogenes or tumor suppressor genes, such as p53, may lead
to mutagenesis, cell cycle arrest, apoptosis and cancer (Hartwig et al., 2002).
On the other hand, the structure and function of many proteins also depend on
metals acting as co-factors. Specifically, metals that can exist in more than one
oxidation state are potentially useful in oxidation-reduction reactions. One major
class of proteins that are affected by metals are the DNA repair proteins. Recently,
there is accumulating evidence that metal ions interfere with DNA repair processes
(Hartwig & Schwerdtle, 2002). Compounds of nickel(II), cobalt(II), cadmium (II)
and arsenic (III) at low, noncytotoxic concentrations, have been shown to inhibit the
removal ofUVC-induced DNA damage (Hartwig & Schwerdtle, 2002; Hartwig et al.,
2002). In addition, Feng et al. (2003) found that chromium increases the amount of
BPDE induced DNA-adducts. Overall, there is a existing hypothesis in the literature,
that the inhibition of DNA repair by metals plays a role in the failure to remove
damaged sites on the DNA; thereby contributing to a los� of genomic integrity, which
may lead to changes in gene expression, increases in DNA damage and
carcinogenesis.
The metal examined in the current study was chromium. Chromium is a
transition metal that can be found in several industrial and natural settings. The most
stable chromium compounds are those with oxidation states of (VI) or (Ill), however,
only chromium (VI) compounds can enter the cell, which normally occurs via a non
specific anion channel (Ding et al., 2002).
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Figure 1: The overall scheme for the reduction of Cr (VI). Modified from Sugiyama,
M.(1991).
Environmental exposure to chromium may occur via rocks, animals, plants,
soil and in volcanic dust and gases(Liu et al., 2001; Singh et al., 1998). Water and
food are other possible sources, however, recent EPA standards for chromium
amounts in municipal drinking water have been reduced such that there is a negligible
risk to humans. The major source of chromium exposure is inhalation or skin contact
from sources such as chrome plating, ferrochrome ore production, stainless steel
welding and lead chromate pigment production(Singh et al., 1998; Ding et al., 2002).
Epidemiological studies indicate long-term exposure to chromium is associated with
respiratory toxicity manifesting as respiratory distress, perforation of the nasal septum
and respiratory tract and skin ulcerations(Singh et al., 1998). The carcinogenic
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potential of chromium (VI) compounds depends on the solubility. Soluble chromates
such as potassium dichromate, used in this study, exhibit a lesser transforming
potential (Singh et al., 1998). This is because once in the cell, chromium (VI) is
readily reduced to chromium (V) (Liu & Shi, 2001), chromium (IV) and chromium
(Ill) (Figure 1). This metabolic reduction is carried out by several different cellular
components, including glutathione, ascorbate or flavoenzymes. The reduction
process generates oxidative stress in the form of reactive oxygen species (Ye et al.,
1999). As an example, reduced chromium (VI), facilitated by flavoenzymes such as
glutathione reductase, generates chromium (V), �hich is unstable and can react with
hydrogen peroxide to generate hydroxyl radicals via a Fenton-like reaction (equation
3)(Ye et al., 1999).

Polyaromatic Hydrocarbon Carcinogenesis

Another class of carcinogenic compounds that are prevalent in the
environment are polyaromatic hydrocarbons. They are organic compounds produced
as by-products of the incomplete combustion of organic substances and are some of
the most potent carcinogens. Sources of PAH include car exhaust, cigarette smoke,
smoked/charcoaled/burnt food, and the coal mining industry. Many polyaromatic
hydrocarbons are inactive and only become carcinogenic once they are metabolized
through a process that yields highly reactive metabolites that readily damage DNA,
RNA and proteins. Mammalian cells recognize polyaromatic hydrocarbons as
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foreign substances that the body tries to remove. In order to secrete these organic
substances, the liver must detoxify them by metabolizing them into water-soluble
products (Huberman and Sachs, 1973). This is accomplished by using the
cytochrome p450 enzymes found in the liver. However, detoxifying organic
hydrocarbons can lead to the formation ofan epoxide, which is a highly reactive
functional group. Conversion to the epoxide is a requirement for polyaromatic
hydrocarbon to become carcinogens and give rise to cellular damage.
Benzo[a]pyrene is a compound derived from the incomplete combustion of
organic materials and major sources ofbenzo[a]pyrene are car exhaust and cigarette
smoke. Although in its natural form benzo[a]pyrene is not carcinogenic, it is
converted to the carcinogenic benzo[a]pyrene diolepoxide (BPDE) by the p450
enzymes within the liver cells ofanimals (Figure 2).
The main mechanism ofcarcinogenesis for BPDE is the formation ofDNA
adducts. DNA-adducts are chemical aberrations ofthe nucleotides that result from
the addition ofa compound to the normal nucleotide. This change makes the normal
nucleotide unrecognizable to other cellular components such as the DNA
polymerases, and therefore leads to either a mistake in pairing during DNA
replication, or halted replication because the polymerases can not pass the adduct. It
has been shown that BPDE has very high and selective affinity for guanine
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Base adduct: benzo[a]pyrene
benzo[ a] pyrene
� metabolic uctivation

benzol a]pyrene diol-epoxi<le (BPDE)
� DNA incorporation

BPDE · DNA adduct

Figure 2: Scheme for benzo[a]pyrene activation and carcinogenesis. Modified from
cmgm.Stanford.edu/biochem/biochem20 I/Slides/DNA%20Repair.
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nucleotides, where the most common site of damage is the N2-guanine (Figure 2)
(Jeffrey et al., 1976).
It has been shown that BPDE induces transversions from Ci:C ➔ T:A (Yang et
al., 1999) and base substitution mutations (Hennig et al., 1995; Wei et al., 1993) in
various cell lines, including human skin fibroblasts which were used in this study.
Fibroblasts are a class of cells found in the epithelial layer of skin. Their main
function is to excrete fibrin, a connective protein that helps preserve the elasticity of
the skin and allows it to repair wounds during the healing process.

Previous Studies

Previous studies in the lab examined the cellular response of normal human
fibroblasts when exposed to chromium and benzo[a] pyrene diolepoxide by analyzing
the cloning ability and hypoxanthine-guanine phosphoribosyl transferase (HPRT)
mutant frequency (Tesfai et al., 1998). Either sequential incubations of the two
carcinogens or co-incubations were examined. Cell treatments were done using the
four combination protocols shown in Figure 3.
The cloning ability of the fibroblasts showed little variation between the four
conditions studied (Figure 3). All protocols reduced cloning ability in a slightly
synergistic manner when cells were treated with both carcinogens. However, the
HPRT mutant frequency indicated an antagonistic response of the two carcinogens
when they are co-incubated (Figure 3: Protocol #2 and #3) as compared with the
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synergistic or additive response of the sequential treatment (Figure 3: Protocol #1 and
#4). In other words, the combined treatment in protocols 2 and 3 produced a lower
frequency of mutation than BPDE alone. 1bis result was independent on whether
there was a preincubation (Protocol #2) or postincubation (Protocol #3) of the
chromium, although the preincubation produced a slightly larger effect.

Protocol #1
48 hr Chromium
Protocol #2
46hr Chromium

k, &hrBPD
2

I ;P�E

2 hr
BPDE

lc,;�PDEI

Protocol #3

EI

46hr Chromium

Protocol #4
48 hr Chromium

Figure 3: Protocols for combined treatments of chromium and BPDE. Modified
from Tesfai et al., 1998.
To elucidate the cellular mechanism by which the antagonistic response was
observed, several hypotheses were tested. The first was that chromium activates
glutathione-S-transferase (GST), which is responsible for binding polyaromatic
hydrocarbons, like BPDE, to glutathione (Hesse et al., 1982; Fields et al., 1998).
Thus, activation of GST would result in BPDE being complexed with glutathione
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before it could react with the DNA. To determine this, glutathione-S-transferase
levels were determined in control cells and treated cells. The results showed that
there was no difference in glutathione activity within the treatment protocols (Codrea
and Reinhold, unpublished data).
Another hypothesis was that the metal was inhibiting the cells from
progressing through the cell cycle, thereby allowing more time for repair of the DNA
before replication occurs. O'Brien et al. (2002) showed that chromium(VI)
incubation can lead to a delay in yeast progressing into S phase. In addition,
Ostrakhovitch et al. (2004) found that both CuSO4 and ZnSO4 resulted in cell-cycle
arrest in the G1 phase, and Xu et al. (1996) showed that chromium could block the
cell cycle at the G1 /S boundary. To assess the contribution of the cell cycle on the
antagonistic decrease in the mutation frequency, normal human fibroblast cells were
synchronized in G0• They were then released from Go in the presence of 3 H
thymidine. Incorporation of 3 H-thymidine into the DNA verified that the cells
entered S phase. If the cells were being halted at the G1 /S interphase, the time of 3H
thymidine incorporation into the DNA would be different between the control and
treated cells. However, this was not the case. All of the treatments incorporated 3H
thymidine at the same time, thereby indicating no effect on the cell cycle.
A third hypothesis was that chromium induced DNA repair processes, which
could then repair DNA damaged by BPDE more efficiently. The research presented
here is meant to test this hypothesis.
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DNA Repair Systems

DNA repair processes are rapidly becoming a topic of study that is gaining
worldwide notice (Bohr, 1991). This is because DNA lesions at critical sites in
oncogenes or tumor suppressor genes may lead to inappropriate cell cycle arrest,
programmed cell death, mutagenesis, genomic instability and cancer (Hartwig et al.,
2002). To minimize these adverse conditions, a complex network of repair syste11_1s
have developed. Depending on the DNA damaging agent identified, cells use several
different mechanisms for repair. Environmental carcinogens such as benzo[a]pyrene
and other polyaromatic hydrocarbons form DNA-adducts, which are removed by
nucleotide excision repair. The nucleotide excision repair pathway consists of the
following sequential steps: damage recognition, incision of the damaged DNA strand
on both sides of the lesion, excision of the lesion-containing oligonucleotide, DNA
synthesis to fill the resultant gap with normal nucleotides and finally, ligation to join
the preexisting and newly synthesized strand termini (Enns et al., 2000). This repair
pathway has two sub-categories: the first is global genomic repair (Figure 4), which
repairs damaged DNA throughout the entire genome. The other is transcription
coupled repair (Figure 5), which readily identifies and repairs the DNA-adducts in
actively transcribing genes (Svejstrup, 2002).
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Figure 4: Schematic for global genomic repair
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Deficiencies in any of the components for global genomic repair (GGR) (Figure 4)
result in a skin disease, xeroderma pigmentosa. The clinical effect of this disease is
an increased sensitivity to light, because ultraviolet light produces DNA damage via
6,4-photoproducts and pyrimidine-dimers, which are repaired using nucleotide
excision repair. There are eight variations of this disease· depending on the factor that
is mutated or non-functioning: XPA to XPG and a variant XPV, which is a defect in a
DNA polymerase that bypasses DNA damage rather than removing it (Araujo &
Wood, 1999). XPC is thought to be the DNA damage recognition factor and essential
for the initiation of GGR. Following recognition, the damage site is surrounded by
the complex XPA-RPA and TFIIH, which is a transcription factor found normally in
cells. TFIIH has two DNA helicase activities XPB (3'➔ 5' polarity) and XPD
(5' ➔ 3' polarity). These unwind the DNA and allow endonucleases XPG (3'incision)
and XPF (5' incision) to remove about 24-32 nucleotides containing the damage site.
The gap in the DNA is then re-synthesized by DNA polymerase and the normal
replication factors.
Molecular deficiencies in transcription coupled repair result in another human
disease termed Cockayne's Syndrome. This disease is clinically diagnosed by
observing the characteristic symptoms within the patients. Some classical symptoms
of this disease are dwarfism, pre-mature aging, decreased muscular function, and
mental retardation. At the molecular level, Cockayne's Syndrome is a deficiency in
the components CSA or CSB in the transcription coupled repair pathway (Figure 5).
When a site of damage is located in an actively transcribing gene, transcription
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Figure 5: Scheme for transcription coupled repair
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coupled repair is the pathway that removes and fixes it before the polymerase pairs
that base. As the polymerase is transcribing the gene, it slowly moves along reading
each base and carefully choosing its complementary base to create the new strand.
However, when the polymerase comes upon a base modified by things such as a
polyaromatic hydrocarbon, it is halted or stalled because "it doesn't recognize the
nucleotide·. The stalled polymerase is a signal for CSA and CSB to complex with the
polymerase and recruit the other repair factors for removal of the modified base
(Svejstrup, 2002). Removal ofthe adduct occurs using many ofthe same components
that are found in global genomic repair, except for XPC, and they perform the same
functions.
Both pathways ofnucleotide excision repair have been shown to be inducible
by carcinogens. Germanier et al. (2000), used UV induced DNA dimers to show that
a priming low UV dose on hamster cells before a toxic UV dose is sufficient to
induce the repair in the transcribed strand of the DHFR gene. They extrapolated this
to hypothesize that transcription-:coupled repair is inducible. Lloyd and Hanawalt
(2002), discovered that p53 induction reduces the number ofbenzo(g)chrysene
adducts by upregulating global genomic repair. ·
This study was undertaken to establish ifthe mechanism for the decrease in
the mutation frequency for normal human fibroblasts, discovered by Tesfai et al.,
involves DNA repair processes. To test this we looked at the number ofadducts
being produced by BPDE to see ifthere is a difference between those cells treated·
with BPDE and those treated with BPDE and chromium. Secondly, since nucleotide
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excision repair is divided into two pathways it was of interest to see if one of these
was responsible for the reduction of adducts. This was studied using fibroblast cell .
lines deficient in proteins necessary for each repair process thereby knocking-out that
pathway of repair. Thirdly, Western blotting was performed to examine p53 and
ubiquitin because these proteins have been found to be important for activation of
nucleotide excision repair (Yang et al., 2003; Nakanishi et al., 2000; Wani et al.,
2000)
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CHAPTER II
MATERIALS AND METHODS
Chemicals
All chemicals used for these experiments came from Sigma-Aldrich Chemical
Company, St. Louis, MO unless otherwise noted. Benzo[a]pyrene diol-epoxide
(Midwest Research Institute, Kansas City, MO) was used at a concentration of 0.30
µM and dissolved in dimethyl sulfoxide (DMSO) (Yang et al., 1982). Potassium
dichromate was the source of chromium (VI) and was dissolved in water and used at
a concentration of 0.30 µM (Tesfai et al, 1998).

Cell Culture

Cell lines used included: normal human fibroblasts (L266-C) derived from
infant human foreskin tissue, nucleotide excision repair deficient XP cells (CRL
1360) from ATCC; human fibroblast primary cell line (GM01888) derived from the
skin of an adolescent; Xeroderma Pigmentosa, complementation group C; XPC
(GM00671B); and Cockayne Syndrome, type 1; CS (GM01856C). The last three cell
lines were obtained from NIGMS Human Genetic Cell Repository, Coriell Institute
for Medical Research.
All cells were cultured in DMEM (Delbecco's Minimal Eagles Medium,
Invitrogen, Grand Island, NY, pH 7.3) supplemented with 0.20 mM serine, 0.20 mM
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aspartate, and 1.0 mM pyruvate and containing 10% supplemented calf serum (SCS)
(Hyclone, Logan, UT), 100.0 units/ml penicillin, 100.0 µg/ml streptomycin and 10.0
µg/ml hydrocortisone at 37°C and 5.0% CO2• The media was changed.using PBS as a
wash approximately every two days. The cells were grown to 80% confluence in
Corning 75 cm2 cell culture flasks, then dislodged using trypsin and transferred to 150
mm x ·25 mm or 100 mm x 20 mm culture dishes for treatment.

Incorporation of 3H-Benzo[a]pyrene

Normal human fibroblasts L266-C cells were grown to 80% confluence in 100
mm x 20 mm culture dishes. Treatments were done as described except the BPDE in
the 2 hour incubation was replaced with 3H-benzo[a]pyrene (3H-BP) (Amersham
Biosciences, Piscataway, NJ). Atypical reaction consisted of the addition of
promutagen (3H-BP), S9fraction (BD Biosciences-Gentest, Woburn, MA) and
cofactors (regenerating system)(BD Biosciences-Gentest, Woburn, MA) in buffer to a
final volume of 3.0 ml. B[a]P was used at a concentration of 0.30 µM, the S9fraction
mix was used at 0.30 mg/ml, 0.60 mg/ml, 0.90 mg/ml and 1.2 mg/ml as indicated.
The cofactor regenerating system consisted of 100 µl of solution A: 1.3 mM NADP+,
3.3 mM glucose-6-phosphate, 3.3 mM magnesium chloride, and 20 µl of solution B:
0.40 U/ml glucose-6-phosphate dehydrogenase. After the 2 hour 3H-BP incubation,
cells were trypsinized and counted. Experiments with a recovery period were refed
DMEM media for the indicated time period. Fibroblast cells were then filtered onto a
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piece ofWhatman filter paper, washed twice with PBS, twice with perchloric acid,
and once with ethanol. The filter paper was then dried and analyzed by liquid
scintillation counting. For DNA measurements, the cells were trypsinized and the
DNA removed using QIAGEN (Valencia, CA) DNeasy kit. Briefly, cells from each
treatment were pelleted and resuspended in 200 µl PBS. To this was added 4.0 µl
(l00mg/ml) RNase A, 20 µl proteinase Kand 200 µl of buffer AL. This was mixed
by vortexing and incubated at 70 °C for 10 minutes. Afterwards, 200 µl of ethanol
was added and mixed thoroughly. This solution was then placed into a DNeasy mini
spin column and washed twice with buffers AWl and AW2. The DNA was then
eluted with buffer AE and the concentration was measure spectrophotometrically
assuming 1 A260 = 50µg. The entire volume of DNA was placed onto a piece of filter
paper and measured by liquid scintillation counting. After the measurement the
scintillation result was normalized for the amount of DNA present and expressed as
scintillation counts per minute per µg of DNA.

32P-Postlabeling Method

Treatments were done on cells at 80% confluence in 150 mm x 25 mm cell
culture dishes. Each treatment protocol was performed on one culture dish of cells.
The concentration of the carcinogens was established using dose-response curves
previously reported (Tesfai et al., 1998). For the kinetic studies the carcinogens were
incubated with the fibroblast cells for the duration reported. PBS was used as a wash
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between all treatment incubations. Fibroblast cells were harvested in phosphate
buffered saline (PBS) and the DNA was extracted using the QIAGEN DNeasy Tissue
kit (as previously described). The DNA was hydrolyzed to (dNp) deoxyribonucleo
side 3'-monophosphates using 5.0 µg of DNA incubated with 0.60 units (6.0 µg) of
micrococcal nuclease and 0.010 units (5.0 µg) of spleen phosphodiesterase in 12 µl
buffer (20 mM sodium succinate, 10 mM CaCh pH 6.0) at 38°C for 3 hrs (Figure 6).
The dNp's were treated with nuclease Pl to remove the 3'-phosphate from normal
nucleotides. Twelve µl of digested DNA was incubated for 40 minutes at 37°C, with
6 µl of buffer containing 1.2 µl of nuclease Pl (5 µg/µl) (Roche,

DNA
Micrococcal Nuclease
Spleen Phosphodiesterase

Xp+Np

Xp+N

Nuclease Pl

T4• polynucleotide kinase
+
[y-32P]ATP

*pXp
Figure 6: Scheme for 32P-postlabelling method. Labels include: normal
nucleotides (N) with phosphate (Np), nucleotide with adduct (X) and phosphate
attached (Xp), and radioactively labeled nucleotide with adduct (*pXp).
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Indianapolis, IN); 3.0 µl of0.25 M sodium acetate (pH 5.0); and 1.8 µl of0.3 M
ZnCh. After incubation, 2.4 µl of0.5 M Tris-base was added. To 20.4 µl ofthe
nuclease Pl treated digest, 6 µl ofa solution containing 2.25 µl L-buffer (300 mM
Tris-HCL; 100 mM MgCh; 100 mM dithiothreitol; 10 mM spermidine, 1.0 µl of [y32P]ATP (10 µCi/µl) (Amersham Biosciences, Piscataway� NJ)) and 0.75 µl ofT4
polynucleotide kinase (3.6 units/µl) with 2.0 µl water was added. The mixture was
incubated at 37°C for 30 minutes.
The 4D:..Thin Layer Chromatography (TLC) procedure characterized by
Gupta, Reddy and Randerath (1982) was used (Randerath and Randerath, 1966;
Reddy and Randerath, 1986; Reddy et al., 1992) to separate labeled DNA adducts
Dl

OR

0---►•
�

D3

'

D4,D5

Figure 7: Scheme for Thin Layer Chromatography
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from free 32 P-ATP. From the freshly prepared digest, 1.5 µl of the modified DNA
was applied to a plastic backed PEI-cellulose sheet obtained from J.T. Baker,
Phillipsburg, NJ. The labeled DNA was oriented at the upper left comer at the point
marked OR (Figure 7). Earlier publications from Randarath's laboratory had separate ·
Dl and D2 solvents, however, later protocols combined these to give the same results
by using just one chromatography solvent labeled as Dl for the protocol used in this
study. Dimension 1 was performed using 1 M sodium phosphate pH 6.8 and 2.5 M
ammonium formate, pH 3.5, onto a 12 cm long Whatman wick, which was stapled to
the top of the cellulose sheet. Upon completion, the Whatman wick was cut off from
the sheet, thereby, removing the unincorporated [y-32P]ATP and the normal
unlabeled nucleotides from the labeling procedure. The sheet was then washed in 500
ml of DI water, and completely dried in a current of warm air. Dimension 3 was run
at a 90° angle to the right from dimension 1 using 3.0 M lithium formate (Aldrich
Chemical Co, Milwaukee, WI), and 7.0 M urea, pH 3.5. This solvent separates the
carcinogen induced DNA adducts. The sheet is allowed to chromatograph until the
solution reaches the top, when it is then removed from the solvent, washed and dried
as described above. Dimension 4 was run at an 180° angle from the direction of·
dimension 1 using a solvent composed of 0.8 M lithium chloride, 0.5 M Tris-HCl,
and 8.5 M urea, pH 8.0. This further separates the DNA modified by adducts. After
completion the sheet is removed from the solvent, washed and dried as described
above. Dimension 5 is done to rel!love any residual background 32P. The solvent
used consists of 1.0 M sodium phosphate, pH 6.8. This is allowed to run until the
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solution reaches the top ofthe sheet. The sheet is then is removed, washed and dried
as described above.
After completion ofthe TLC separation, the sheet was placed in a cassette
with film. The cassette was wrapped in aluminum foil to ensure complete darkness
was maintained. The wrapped cassette was then placed at -80°C for 36 hours.
Development was done using Kodak GBX developer and fixer.
The section ofthe sheet that contained the DNA adducts was determined by
the exposed film and was scraped off ofthe TLC sheets. The amount ofcellulose
used for counting was consistent within an experiment and was determined by the
largest spot size obtained for each experiment. The cellulose was added to 10 ml of
CytoScint (ICN, Irvine, CA) in a glass scintillation vial. Scintillation was performed
using a Beckman scintillation counter, three times for 10 minutes.

Western Blot Analysis

Human fibroblast cells (L266-C) were grown to 80% confluence as previously
described using three 100 mm x 20 mm dishes per treatment. After treatments the
cells in each dish were lysed using 500 µl oflysis buffer (20 mM Tris pH. 7.4, 150
mMNaCl, 1.0 mM EDTA, 1.0 mM EGTA, 1% Triton). A colormetric system from
BIO-RAD Laboratories (Hercules, CA) was used to determine the amount ofprotein
per sample. Briefly, 25 µl ofsample and standards ofbovine serum albumin, made
fresh for every assay performed and used at 50 µg, 40 µg, 30 µg, 20 µg, and 5.0 µg,
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were placed into microcentrifuge tubes. To this was added 125 µl of RC reagent I,
. the tubes were vortexed, then 125 µl of RC reagent II was added to each and
centrifuged at 15,000 x g for 4 minutes. The supernatant was discarded onto an
absorbent tissue and 127 µl of Reagent N (5.0 µl of DC reagent Sand 250 µl of DC
reagent A, for each sample tested) was added, mixed and ·allowed to sit for 5 minutes
or until the pellet was dissolved. lbis was vortexed again before proceeding. Then
1. 0 ml of DC reagent B was added to each tube, vortexed immediately and incubated
at room temperature for 15 minutes. Absorbencies were read at 750 nm to establish a
standard curve and the amount of protein per sample (Figure 8).

Protein standard curve
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Figure 8: Example of standard curve produced from protein standards
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Samples were normalized for protein and 20 µl of appropriate ratios of sample
and lysis buffer were placed into a 1.5 ml microcentrifuge tube with 5.0 µl of 5X
sample buffer containing: 0.5 M Tris-HCl (pH. 6.8), 2-mercaptoethanol, glycerol
(25%), 10% SDS, 0.50% bromophenol blue in water. The samples were heated at 95100°C for 5 minutes, cooled in ice and quickly centrifuged. They were then loaded
into a 12% SDS-acrylamide gel (Invitrogen, Grand Island, NY) along with the
biotinylated protein ladder (Cell Signaling Technology Beverly, MA). The samples
were run at 80V for approximately 2 hours to separate the whole cell lysate proteins.
Transfer of the. proteins was done using a Xcell II Blot Module (Novex Experimental
Technology, San Diego, CA) at 40V for one and a half hours onto a PDVF
Membrane (Invitrogen, Grand Island, NY). After transfer, the membrane was washed
in DI-water for 5 minutes, and placed into blocking buffer (IX TBS and 3% non-fat
dry milk) for 1 hour. The membrane was then washed again with DI-water 3 times
for 5 minutes each. It was then incubated in a sealed plastic bag with 10 ml of
blocking buffer and a 1: 1000 dilution of mouse monoclonal a-p53 antibody (Upstate,
Lake Placid, NY) or 1: 1000 dilution of ubiquitin (P4D 1) monoclonal antibody (Cell
Signaling Technology, Beverly, MA) overnight at 4°C. The next day the membrane
was washed 3 times for 5 minutes each with DI-water, and incubated at room
temperature for 1 hour in blocking buffer and a 1:5000 dilution of a-mouse lgG
conjugated with horseradish peroxidase (Upstate, Lake Placid, NY) and 1: 1000
dilution of a-biotin, HRP-linked antibody (Cell Signaling Technology, Beverly, MA).
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After incubation; the membrane was rinsed with lX TBS with 0.1% Tween-20 for 5
minutes. It was then rinsed with DI-water for 1-1 ½ hours.
The membrane was incubated with the Lumiglo chemiluminescent substrate
system (.KPL, Gaithersburg, MD) for I minute then placed in a cassette with film for
various times. Development of the film was done using Kodak, GBX developer and
fixer. Analysis was performed using a Macintosh computer with the public domain
NIH Image program (developed at the U.S. National Institutes of Health and available
on the internet at http://rsb.info.nih.gob/nih-imagel).

Affymetrix Genechip Analysis

Human fibroblast cells (L266-C) were grown to 80% confluence as previously
described in 150 mm x 25 mm dishes, one per treatment. Total RNA was isolated
from treated cells using QIAGEN RNeasy mini kit. Briefly, the cells were collected
in PBS and pelleted by centrifugation. They were disrupted by the addition of 350 µl
RLT buffer mixed with a 1% dilution of P-mercaptoethanol_. The sample was then
homogenized by passing the lysate through a 20-gauge needle fitted to an RNase-free
syringe. To the lysate was added 350 µl of 70% ethanol and mixed well. Then the
mixture was placed into an RNeasy mini column and centrifuged for 15 seconds. It
was washed with 700 µl of buffer RWl then twice with 500 µl of buffer RPE.
RNase-free water was then used to elute the samples. The concentration was measure
spectrophotometrically assuming 1 A260 = 40µg.
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Figure 9: Scheme for Affymetrix analysis. Modified from www.mta-world.de/
html/affymetrix.html.
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All Affymetrix reagents are purchased within the Affymetrix gene chip
system (Santa Clara, CA) and distributed by Invitrogen (Grand Island, NY) (Figure
9). Reverse transcriptase PCR was performed by incubating 8.0 µg of total RNA with
T7-(dT)24 primer , 5'-GGCCAGTGAATTGTAATACGTACTCACTATAGGGAGC
GG-(dT)24-3 ', for 10 minutes at 70 °C. After which, 0.1 M DTT, 10 mM dNTP,
Superscript II 200 U/µl and 5X first strand buffer were added and the reaction
mixture was incubated at 42 °C for 1 hour. The second strand synthesis was
performed by adding: 5X 2nd strand buffer, 10 mM dNTP, DNA ligase 10 u/µl, DNA
pol I 10 u/µl, RNAse H 2 u/µl and incubating at 16 °C for 2 hours. T4 DNA
polymerase 5 u/µl was then added and incubated at 16 °C for 5 minutes. After which,
0.5 M EDTA was added to stop the reaction.
The cDNA was then cleaned and precipitated with sequential ethanol washes
and centrifugation at 12000 x g. The ethanol was then removed by letting it air dry
under a light, and the DNA was resuspended in DEPC-treated water. To make
biotinylated cRNA from the cONA reagents, 1OX HY buffer, 1OX biotin
ribonucleotides, lOX DTT, lOX RNAse inhibitor mix, and 20X T7 polymerase, were
added and mixed approximately every 45 minutes for 4.5 hours. Biotinylated cRNA
purified with the QIAGEN RNeasy kit was eluted with 30 µl Rnase-free water and
measured spectrophotometrically.
A master mix of control herring sperm DNA (10 mg/ml) with control oligos
was prepared and added to the prepared fragmented cRNA. Then SAPE staining
solutions and antibody solution mix were hybridized to the chip. Affymetrix human
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genome U95Av2 chips (Santa Clara, CA) were warmed to room temperature and
prehybridized for 40 minutes with hybridization buffer. Then the biotinylated cRNA
was placed into the chip and hybridized overnight. The next day, the chip was
washed and stained with the prepared solutions according to the fluidics station
protocol and the Affymetrix system. The data obtained was analyzed using the
Spotfire Decisionsite software package version 7.2 (Somerville, MA).

RT-PCR for Ubiquitin

Custom DNA primers were obtained from Invitrogen (Grand Island, NY) with
the forward primer sequence as 5'- GGAATGCAACTITATTGAAAGG-3' and
reverse primer sequence as 5'- GAGAATGTCAAGGCAAAGATCC -3'. Ten pmol
of each primer was incubated with AMY-reverse transcriptase (Sigma, St. Louis,
MO) in PCR buffer, MgCh (2.5 µM), deoxynucleotides (200 µM), DNA polymerase
and template RNA (1 µg). This reaction mix was placed into a 0.20 ml tube and
placed into a thermocycler. Synthesis of cDNA was done at 48°C for 30 minutes,
then denatured at 94°C for 2 minutes. The PCR reaction was run for 20 cycles of
denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, then extension
at 72°C for 1 minute. After which, a final extension period was done at 72°C for 7
minutes. The PCR products were analyzed by separating in a 1.5% agarose DNA gel
containing ethidum bromide.
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Statistical Analysis

Results for the 32P-postlabeling experiments were analyzed using a t-test for
comparison of two-means. Significance was established at a = 0.05. Results for the
Western Blot analy�s were calculated using one-way ANOVA for comparison of
means. The data was analyzed using the Student-Newman-Kuels test for
comparisons within the groups. Significance was established at a = 0.05. Graphical
representations show error bars based on the standard deviation of the samples.
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CHAPTER III
RESULTS
Several researchers have studied the effects of carcinogens on hwnan cellular
systems. Polyaromatic hydrocarbons such as benzo[a]pyrene diolepoxide (BPDE) are
know to cause DNA damage in the form of DNA adducts. These adducts are repaired
by the nucleotide excision repair pathway using either .global genomic repair (Figure
4) or transcription coupled repair (Figure 5). Previous results from our laboratory
have shown that under certain conditions, the mutation frequency of BPDE in normal
hwnan fibroblasts can be reduced by chromiwn treatment (Tesfai et al., 1998). The
results shown here provide evidence that nucleotide excision repair is responsible for
the reduction.
Tesfai et al., (1998) established four treatment protocols (Figure 3) to analyze
the effect of chromiwn and benzo[a]pyrene diolepoxide on hwnan skin fibroblasts.
They fo1 nd that the mutation frequency for L266-C normal hwnan fibroblasts varied
depending upon the protocol tested. Of those treatments used, protocol #2 (Figure 3)
gave the greatest antagonistic reduction in the mutation frequency. Therefore, this
was the protocol used in this study for all of the cell lines (Figure 10).
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Figure 10: Treatment conditions. All of the treatments were performed on 80%
confluent cultures in all cell lines used for this study.
Determination of BPDE Adducts
To determine if the number ofDNA adducts formed by BPDE positively

correlated with the reduction of the mutation frequency previously reported by our
laboratory (Tesfai et al., 1998; Hamdan et al., 1999), we attempted to use a

radiolabeled BPDE and measure the amount of adducts formed and the repair of those

adducts. 3H-BPDE, however, was no longer commercially available so a natural

alternative was to use 3H-benzo[a]pyrene and transform it in vitro to the ultimate

carcinogen BPDE (Watson et al., 1990; Savela et al., 1996; Borenfreund&P uemer,
1987;Chen et al., 1982). To accomplish this, cells were incubated with 3 H

benzo[a]pyrene, liver extracts encompassing the S9 fraction containing the
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cytochrome p450 enzymes, and a NADPH enriched solution. The S9 fraction was
needed since human fibroblasts do not have an active p450 system. This method,
however, did not show 3H-benzo[a]pyrene incorporation into the DNA. This may be
because studies in the literature use serum free media whereas we were using serum
containing media. Therefore, this question needed to be addressed by another
method.
The 32P-postlabeling system was used to discover if the reduction of mutation
frequency was due to a decrease in the amount of DNA-adducts being produced by
the BPDE. An essential part of the assay is to establish mononucleotides from the
DNA obtained. This is facilitated by spleen phosphodiesterase (EC 3.1.4.18), and
micrococcal nuclease (EC 3.1.31.1). Phosphodiesterase enzymes hydrolyze DNA in
the 5' - 3' direction to excise 3'-phosphomononucleosides. This enzyme is specific
for the 5'-end of an oglionucleotide after it has been converted to a 5'-0H by
micrococcal nuclease. Calcium chloride is contained in the buffer because
micrococcal nuclease, an extracellular nuclease of Staphylococcus aureus, has an
absolute enzymatic requirement for Ca2+. Sodium succinate is added to the buffer to
maintain the optimum pH for the enzymes (6.0) (Reddy and Randerath, 1986).
After digestion is complete, nuclease Pl is added to remove the 3'-phosphates
to form mononucleotides with 3'-OH (Phillips, 1996; Reddy and Randerath, 1986).
Based on the size and steric hindrance of the adducted nucleotide formed by BPDE,
nuclease Pl will only remove the 3'-phosphates from the nucleotides that do not
contain an adduct.
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Labeling of the DNA-adducts with [y-32P]ATP is performed with T4
polynucleotide kinase, a conimon enzyme that adds a phosphate to the 5'-end of the
adduct modified mononucleotides. The TLC system is then employed to separate the
mononucleotides and urea is used in varying concentrations in D3 and D4 to release
the hydrophobic interaction of the adduct from the cellulose sheets. The degree of
this release determines how quickly the nucleotides will move across the cellulose
sheet and therefore facilitates the separation of the differing mononucleotides.
Control and chromium treated cells (Figure 10) did not produce any spots on the TLC
cellulose sheet and are therefore not included in the data presented.
L266-C cells from normal infant human foreskin fibroblasts were treated with
chromium and BPDE as described above and assayed for adduct formation (Figure
I la). Using the amount of adducts produced by BPDE alone to be defined as 100%,
the results of the combined treatment showed a significant reduction (60%) in the
number of adducts present (Figure 11b).
To ensure reproducibility, another cell line of normal human fibroblasts from
an adolescent (NHFB) was treated as described and assayed using the 32P
postlabeling system (Figure 12a and 12b). Similar results to those reported for the
neonatal fibroblasts (Figure 11a and 11b) were obtained.
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Figure 11b: Accumulative 32P-postlabeling results ofL266-C normal human
fibroblasts. Graph represents data from four experiments. The star indicates
statistical significance.

Our hypothesis states that the reduction in the number ofDNA-adducts is due
to an induction in nucleotide excision repair. Nucleotide excision repair is composed
oftwo distinct pathways: transcription-coupled repair, and global excision repair.
Human fibroblasts cells deficient in each ofpathways were used in the 32P
postlabeling system to establish which may be involved in the reduction ofDNA
adducts produced l:>y BPDE.
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NHFB BPDE

NHFB Cr & BPDE
Figure 12a: 32P-postlabelling data from normal human adolescent fibroblast cells.
This is one set of representative autoradiographs from three experiments performed.
The dashed square represents the part of the sheet that was scraped for scintillation
analysis.
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Figure12b: Accumulative 32P-postlabeling results ofNHFB normal human
adolescent fibroblasts. Graph represents data from three experiments. The star
indicates statistical significance.

Cockayne syndrome (CS) is a disease state in which the cells are deficient in
transcription-coupled repair. The deficient factor is usually CS-A or CS-B, both of
which are thought to be required for recognition of the halted polymerase at the site
of a lesion (Figure 5). Cockayne Syndrome fibroblasts cells were treated as described
with BPDE and Cr & BPDE and assayed by 32P-postlabeling.
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CS BPDE

CS Cr&BPDE
Figure 13a: 32P-postlabelling data from Cockayne Syndrome fibroblasts. This is one
set of representative autoradiographs from three experiments performed. The dashed
square represents the part of the sheet that was scraped for scintillation analysis.
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Figure 13b: Accumulative 32P-postlabeling results .of Cockayne Syndrome fibroblasts.
Graph represents data from three experiments. The star indicates statistical
significance.

Figure 13 a & b shows that Cockayne Syndrome cells have the ability to
reduce the number of DNA-adducts upon treatment with chromium. So even though
these cells do not have transcription-coupled repair they are still able to reduce the
number of DNA-adducts. This suggests that transcription-coupled repair is not the
main mechanism for the reduction of the BPDE induced DNA-adducts.
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Figure 14b: Accumulative 32P-postlabeling results of CRL-1360 nucleotide excision
repair deficient human fibroblasts. Graph represents data from three experiments.

We then examined whether defects in global genomic repair would effect the
response. Two cell lines of xerodenna pigmentosa fibroblasts were treated with the
protocol described previously"(Figure 10) and analyzed using the 32P-postlabeling
system. CRL-1360 cells are deficient in global genomic repair and were used to
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Figure 15b: Accumulative 32P-postlabeling results for XPC Xeroderma Pigmentosa
human fibroblasts. Graph represents data from three experiments. The star indicates
statistical significance.•

establish ifthe decrease in the number of adducts was due to this pathway. Figure
14a and 14b shows the 32P-postlabeling TLC sheets ofCRL-1360 DNA did not show
a decrease in the amount ofBPDE induced DNA-adducts in chromium treated cells.
In fact, there appeared to be an increase with chromium although this increase was
not significant. Therefore, without global genomic repair, chromium treated
fibroblasts are unable to reduce the number ofDNA-adducts.

45

The loss of the antagonistic effect was substantiated using a second fibroblast
cell line from a patient with Xeroderma Pigmentosa, a disease state in which the cells
are deficient in global genomic repair. In this cell line (XPC) the deficient factor is
XPC, the recognition factor for identification of damage in this pathway. These
fibroblasts showed a significant increase in the number of DNA-adducts in the
combined treatment as opposed to the antagonistic effect shown in the normal human
fibroblasts (Figure 15a and 15b).
The [y-32P]ATP 32P-postlabeling method shows that normal human fibroblast
demonstrated a significant decrease in the total amount of DNA-adducts produced
from BPDE binding when a pre-incubation with chromium (0.3 µM) was introduced
46 hours before and was continued during the BPDE treatment. Cells deficient in
transcription-coupled nucleotide excision repair showed results similar to those for
normal cells. Fibroblasts defective in global genomic nucleotide excision repair,
however, showed no significant difference or an increase in the number of BPDE
DNA-adducts under these same conditions. These results support the hypothesis that
the reduction in DNA-adducts from BPDE in combination with chromium involves
global genomic nucleotide excision repair.
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. P53 Expression

In normal human fibroblasts, p53 has been found to be an essential factor in
the cells ability to induce global genomic repair (Wang et al., 2003). We wanted to
discover if p53 was being induced to help facilitate the decrease in the number of

A

200%

e
0
0

*

*

250%

150%
100%

0

50%

B

0%
Control

Cr

BPDE

Cr& BPDE

Figure 16: p53 Western Blot analysis of normal human fibroblasts (L266-C). (A)
Top panel shows a representative blot while the (B) bar graph is a composite of six
experiments. Stars indicate conditions that are significantly higher than the controls
(ANOV A p<0.05).
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though an increase was seen in all treatments there was no difference in the amount of
p53 between the BPDE and the combined treatments.

Ubiquitin Expression

Human microarray chips (U95Av2) from Affymetrix were used to give an
overall analysis of the genomic affects of the treatments on fibroblast cells. Total
RNA was used as a template for the production of cDNA. A complementary strand
was then made and labeled with biotinylated nucleotides, and hybridized to the
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Figure 18: Affymetrix analysis, numbers represent fold increase over control as
indicated by Spotfire analysis.
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Affymetrix human genome chip (U95Av2). Using the Spotfire Decisionsite software
(Somerville, MA) the relative frequencies of hybridization were analyzed. It
indicated that several genes were modified in the various treatments compared with
the control. The analysis also showed several genes that seemed to increase
synergistically with the combined treatments rather than the BPDE or chromium
treatment individually. These genes were mostly associated with transcription
processes, the cell cycle, or protein degradation. The ubiquitin gene, in particular,
showed a significant, almost synergistic, increase with the combined treatment
(Figure 18) in the Affymetrix system and has been shown to be associated with
nucleotide excision repair (Yang et al., 2003; Nakanishi et al., 2000). It is thought
that ubiquitin targets the histone proteins for degradation thereby releasing the coiled
DNA and allowing the repair components access to the sites of damage throughout
the genome (Groisman et al., 2003).
In order to verify the Affymetrix genechip data, it was necessary to look at
ubiquitin using a more direct method. To accomplish this, reverse-transcriptase PCR
(RT-PCR) was performed on samples from normal human fibroblast cells (L266-C)
that were treated with the carcinogens as described and the RNA was collected. A
sequence specific ubiquitin probe was used to produce complementary DNA strands,
which were then run on a gel for identification. The results showed that the mRNA
of ubiquitin was expressed in each of the treatments (Figure 19).
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Figure 20: Ubiquitin Western Blot analysis in normal human fibroblasts (L266-C).
(A) Top panel shows a representative blot with a 10-200 kDa protein ladder, while
the (B) bar graph is a composite of four experiments.
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CHAPTER IV
DISCUSSION
Environmental carcinogens have been the source of many studies with the
goal of discovering the mechanism by which they elicit a carcinogenic response.
Studying the action of a single carcinogen on a particular system is necessary and
·useful, however, it may not represent real situations where cells are exposed to many
carcinogens at the same time. Thus, determining how cells respond to multiple
carcinogens is crucial. Even though studies examining the cellular effect of multiple
carcinogen treatments are limited, they seem to show that the carcinogens elicit either
a synergistic or antagonistic response to the overall potential for cellular damage
depending on the specific conditions used.
The effect of multiple carcinogens has been studied using metals and
polyaromatic hydrocarbons or metals and ultraviolet light. Balansky et al.(2000)
studied mice exposed to mainstream cigarette smoke and potassium dichromate.
They looked at early cell markers, which indicated that Cr(VI) and cigarette smoke
had an increased, but less than additive carcinogenic response. A synergism was
found by Liu et al.(1999) when they looked at DNA strand breaks caused by
chromium(VI) and cigarette smoke. Rivedal & Sanner(1981) also showed a
synergistic effect after combined treatments of nickel(II), cadmium(II) and
chromium(VI) with benzo[a]pyrene. Several authors comment that the synergistic
effect is probably due to an inhibition of DNA repair processes by the metal. In some
instances metals have also been shown to displace the nucleotide excision repair
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complexes not allowing them access to damaged DNA. Several studies from
Hartwig's laboratory show repair inhibition by nickel of DNA damage caused by
oxidative stress (Dally & Hartwig, 1997), ultraviolet light (Hartmann & Hartwig,
1998; Hartwig & Beyersmann, 1989), and benzo[a]pyrene (Schwerdtle et al., 2002).
These studies suggest that inhibition of DNA repair processes may be one mechanism
for metal carcinogenesis.
Although many studies that use metals and polyaromatic hydrocarbons show a
synergistic effect between the carcinogens, in certain situations, an antagonistic
response is also observed. As an example, Vaglenov et al. (1999) found that
electroplate exposed workers have increased levels of chromium exposure compared
with control groups. When y-irradiated, the lymphocytes of the workers exposed to
chromium showed a significant resistance to the possible damage. The antagonistic
effect has also been shown in lung cells of mice, where Balansky (1995) evaluated
the combination of mainstream cigarette smoke and urethane. Katsi:fis et al., 1996
found an antagonistic effect with nickel and either ultraviolet light, X-rays or
chromium, showing that there were less sister chromatid exchanges in the cells
treated with nickel and the carcinogen than with carcinogen alone. An antagonistic
effect was also seen in previous studies from our lab using potassium dichromate or
nickel subsulfide and BPDE in human :fibroblasts (Tesfai et al., 1998; Hamdan et al.,
1999). One explanation given for the antagonistic result is that a low dose of a
carcinogen can protect the cells from a carcinogenic substance by inducing DNA
repair processes. As an example, Maeda et al. (2001) studied normal human
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keratinocytes exposed to doses ofUV-B. They found that low doses ofUV-B induce
expression of nucleotide excision repair genes while high doses downregulate
expression. They also performed a pre-incubation study where low dose UV-B was
irradiated on the cells before a higher dose. They found that keratinocytes, treated
with the low doses, were protected from subsequent high exposure doses. This
coping mechanism is consistent with the previous work in our laboratory which
shows a low dose of chromium protecting the fibroblasts from the harmful BPDE.
The results presented here confirm the antagonistic effect reported earlier in
our laboratory (Tesfai et al., 1998; Hamdan et al., 1999) showing that there is a
correlation between the number of DNA-adducts being produced and the mutant
frequency observed. This is important because the endpoint of the previous
experiments was a measurement of mutations at the HPRT locus, which is an indirect
effect of chromium and BPDE. However, this study analyzes the direct interaction of
BPDE in forming DNA-adducts in normal human fibroblasts (Figure 11 and 12).
In order to assess the relationship between the antagonistic effect of the
multiple carcinogen treatment and DNA repair, we used cells deficient in nucleotide
excision repair. XP cells were tested to assess global genomic repair and cells from a
patient with Cockayne's Syndrome (CS) were tested to assess transcription-coupled
repair (Hanawalt, 1996), using the 32P-postlabeling system. Labeling of the BPDE
adducts showed that XPC cells, which are deficient in the factor used to recognize the
lesion on the DNA, had a significant increase in the number of DNA-adducts in the
presence of both chromium and BPDE when compared to BPDE alone (Figure 15a
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and 15b). CRL-1360 cells, which are also XP cells deficient in nucleotide excision
repair (Figure 14), had an increase in the number ofBPDE induced adducts in the
combined treatment as well, but it was not a significant increase. This increase is
probably due to the fact that XPC cells have an absolute deficiency in global genomic
repair (Figure 15b) and is consistant with the work ofTang et al. (2002) showing
tissue deficient in XPD activity containing more polyaromatic hydrocarbon adduct
than control tissue. On the other hand, the Cockayne's Syndrome (CS) cells were
able to reduce the number of DNA-adducts in the combined treatment (similar to the
normal fibroblasts) even without a functional transcription-coupled repair mechanism
(Figure 13). Thus, reduction in DNA-adducts with chromium treatment appears to be
contingent upon repair using the global genomic pathway.
In order for the global genomic repair pathway (Figure 4) to efficiently repair
DNA damage it requires p53 (Hwang, 1999). Lloyd and Hanawalt (2000) studied
this as it relates to the ability ofa cell to repair BPDE adducts. They found that cells
without p53 showed no repair ofBPDE adducts, while those cells with p53 had the
adducts repaired within 24 hours. Wani et al. (2000) also studied the effects ofa
functional p53 protein in cells damaged by BPDE. They discovered that cell lines
with a functional p53, a mutant p53 and a null p53 all incorporated the same amount
ofBPDE into the DNA; however, the repair ofthese adducts was dependent upon the
function ofp53 and was enhanced by having a normal functional p53 protein. p53 is
also a cell cycle protein that is used at interphases to sense damage to the DNA and
arrest the cell cycle so repair can take place (Boulikas, 1996; Levine, 1997).
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Induction of p53 decreases the mutagenesis caused by ultraviolet light in mouse cells
(Yuan et al., 1995) and is required for the induction ofXPC and global genomic
repair in human cell lines (Amundson et al., 2002). Based on this knowledge, we
decide to examine whether p53 might be involved in the antagonistic effect observed.
It is known that both carcinogens used in this study, chromium (Wang et al., 2000)
and BPDE (Wani et al., 2000), can induce p53 levels. It was possible that chromium
and BPDE produced a synergistic induction of p53 which resulted in a synergistic
induction in DNA repair. Our data shows an increase in p53 with BPDE was
observed, but there was no further increase with the chromium pre-incubation
(Figure 16). This data suggests that any induction of nucleotide excision repair may
be p53-independent. There is evidence for this type of mechanism. Hartman & Ford
(2002) tested the breast cancer gene, BRCAl, to see if it would affect BPDE induced
adducts when over-expressed. They found that BRCAI, independent of p53
activation, enhanced XPC expression in breast cancer tumor cells. It is possible,
therefore; that a p53-independent increase in the recruitment ofXPC to the DNA site
of damage occurs in the presence of chromium. It should be mentioned that a
functional p53 has been shown to be necessary for repairing bulky DNA- adducts
using global genomic repair (Wang et al., 2003), and our cells do contain p53. · The_
level of p53 must be sufficient for global genomic repair, but induction occurs by
chromium via a p53-independent mechanism.
To give an overall view of other genes being affected by the treatments,
Affymetrix gene chip technology was used. One gene that was significantly
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increased in the combined chromium and BPDE treatment versus BPDE alone was
ubiquitin. Ubiquitin is known as a gene that is instrumental in apoptosis and protein
degradation, but it has also been implicated as having specific ties to DNA repair
systems (Yang et al., 2003; Nakanishi et al., 2000; Spence et al., 1995). During
global genomic repair ubiquitin may have a role in allowing the DNA repair proteins
access to the site of damage. Groisman et al. (2003) discovered that ubiquitin was
necessary for the release of DNA from the nucleosome by targeting the nucleosome
for degradation. This allows the bound DNA to become free and provide room for
the nucleotide excision repair proteins to fix the lesion. Furthermore, ubiquitin
facilitates the removal of stalled or arrested RNA polymerase II at a site of damage
during transcription, so that transcription-coupled repair factors can repair the damage
(Yang et al., 2003). In normal transcription, TFIIH, a transcription factor which has
cdk7 kinase associated with it, phosphorylates RNA polymerase II after transcription
has taken place. This then signals RNA polymerase II for degradation. This is also
thought to be the signal for ubiquitination and degradation of stalled RNA polymerase
II in transcription-coupled repair (Lommel et al., 2000). Bergman et al. (1996) also
found that Cockayne Syndrome-A and Cockayne Syndrome-B deficient cells are
unable to ubiquinate RNA polymerase II, which may be a reason why Cockayne
Syndrome cells are deficient in transcription-coupled repair.
Further verification of the data found from the Affymetrix system is needed
because genechip technology is used to give an overall trend and not an exact amount
or level of RNA expression. Therefore, reverse transcriptase PCR was done to study
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the ubiquitin m.RNA from the treatments used in this study (Figure 19). Western
blotting for the protein ubiquitin was also done to see ifubiquitin protein is induced.
Our data shows that ubiquitin is not increased within these treatments (Figure 20).
This discrepancy exists most likely because the Affymetrix data was performed only
once for each treatment. Therefore, the RNA sample used may not be a true
representative for the overall genomic conditions imposed by the carcinogens.
Another option is that ubiquitin is being used more efficiently. Therefore, not
changing the overall protein levels ofubiquitin; but changing how it is distributed
within the cell.
This study was designed to gain understanding into the mechanism by which
chromium can cause a reduction in the mutagenic effect ofbenzo[a]pyrene diol
epoxide in normal human skin fibroblasts. This effect was seen in normal human
fibroblasts and Cockayne Syndrome fibroblasts, but not in XP fibroblasts. This
suggests that global genomic repair is important for the antagonistic effects and
appears to be independent ofp53 or ubiquitin induction. Further studies will be
needed to establish the exact mechanism by which the pre-incubation ofchromium
inhibits BPDE induced DNA-adducts. This study only examined human skin
fibroblasts; therefore, it will be important to repeat these experiments with different
cells types to see ifthe effect is specific for skin fibroblasts or ifthere is a general
mechanism involved.
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